NCT01385956View on ClinicalTrials.gov

SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

November 30, 2014

Conditions
Pancreatic Cancer
Interventions
DRUG

SOM 230 LAR

We will attempt dose escalation starting at a lower level 1 of 40 mg since we are using SOM 230 LAR in combination with gemcitabine for the first time.

DRUG

Gemcitabine

Fixed dose: 1000mg/m\^2 weekly x3 then 1 week off

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER